Skip to content

Blueprint Medicines Corp

Delisted

CIK 1597264fmd_0HTQHMF5PRZ1MG51Z6N0DDYVS5Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2013 to Mar 31, 2025, 46 periods

Latest annual · FY2024

Millions
Total revenues
509
Gross profit
489
Net income
(67)
Free cash flow
(197)

Latest quarter · Q1 FY2025

Millions
Total revenues
149
Gross profit
147
Net income
0
Free cash flow
(56)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2021 to FY2024
+41.4%
Revenue, 5 yearsFY2019 to FY2024
+50.2%
Net income, 5 yearsFY2019 to FY2024
n/m

Blueprint Medicines Corp financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2024FY2023ChangeSource
Revenue$508.8 million$249.4 million+104%10-K 2025-02-13 · proof
Gross profit$488.7 million$240.8 million+102.9%10-K 2025-02-13 · proof
Net income-$67.1 million-$507 million10-K 2025-02-13 · proof
Cash from operating activities-$192.6 million-$436.8 million10-K 2025-02-13 · proof
Free cash flow-$197.2 million-$452.9 million10-K 2025-02-13 · proof
Total assets$1.2 billion$1 billion+12.4%10-K 2025-02-13 · proof
Total liabilities$881.1 million$918.6 million-4.1%10-K 2025-02-13 · proof
Cash and cash equivalents$102 million$71.3 million+43.1%10-K 2025-02-13 · proof
What was Blueprint Medicines Corp's revenue in fiscal 2024?
Blueprint Medicines Corp reported revenue of $508.8 million for fiscal 2024 (the year ended Dec 31, 2024), against $249.4 million the year before (+104%). Source: the 10-K filed with the SEC on Feb 13, 2025. SEC
What was Blueprint Medicines Corp's gross profit in fiscal 2024?
Blueprint Medicines Corp reported gross profit of $488.7 million for fiscal 2024 (the year ended Dec 31, 2024), against $240.8 million the year before (+102.9%). Source: the 10-K filed with the SEC on Feb 13, 2025. SEC
What was Blueprint Medicines Corp's net income in fiscal 2024?
Blueprint Medicines Corp reported net income of -$67.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$507 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2025. SEC
What was Blueprint Medicines Corp's cash from operating activities in fiscal 2024?
Blueprint Medicines Corp reported cash from operating activities of -$192.6 million for fiscal 2024 (the year ended Dec 31, 2024), against -$436.8 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2025. SEC
What was Blueprint Medicines Corp's free cash flow in fiscal 2024?
Blueprint Medicines Corp reported free cash flow of -$197.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$452.9 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2025. SEC
What are Blueprint Medicines Corp's total assets?
As of Dec 31, 2024, Blueprint Medicines Corp reported total assets of $1.2 billion, against $1 billion a year earlier (+12.4%). Source: the 10-K filed with the SEC on Feb 13, 2025. SEC
What are Blueprint Medicines Corp's total liabilities?
As of Dec 31, 2024, Blueprint Medicines Corp reported total liabilities of $881.1 million, against $918.6 million a year earlier (-4.1%). Source: the 10-K filed with the SEC on Feb 13, 2025. SEC
What are Blueprint Medicines Corp's cash and cash equivalents?
As of Dec 31, 2024, Blueprint Medicines Corp reported cash and cash equivalents of $102 million, against $71.3 million a year earlier (+43.1%). Source: the 10-K filed with the SEC on Feb 13, 2025. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1597264&period_type=annual&limit=5"

Information only, not investment advice.